--- title: "BRP | PepTracker Pro" description: "A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "BRP", "description": "A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models.", "url": "https://peptrackerpro.com/peptides/brp", "lastReviewed": "2026-05-16", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "BRP", "item": "https://peptrackerpro.com/peptides/brp" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following obesity drug development news?", "acceptedAnswer": { "@type": "Answer", "text": "BRP is a research peptide studied in preclinical models. A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models." } }, { "@type": "Question", "name": "Those interested in AI-driven drug discovery?", "acceptedAnswer": { "@type": "Answer", "text": "BRP is a research peptide studied in preclinical models. A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models." } }, { "@type": "Question", "name": "Researchers tracking novel appetite regulation mechanisms?", "acceptedAnswer": { "@type": "Answer", "text": "BRP is a research peptide studied in preclinical models. A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models." } }, { "@type": "Question", "name": "People seeking alternatives to GLP-1 drugs with fewer side effects?", "acceptedAnswer": { "@type": "Answer", "text": "BRP is a research peptide studied in preclinical models. A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ BRP **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # BRP Low Evidence A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models. Aliases BRINP2-Related Peptide +2 more Evidence Low Evidence Last Updated 2026-05-16 Reading Time 3 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Why Researchers Study It](#why-researchers-study) 4. [Proposed Mechanisms](#proposed-mechanisms) 5. [Evidence Snapshot](#evidence-snapshot) 6. [Commonly Discussed Benefits](#benefits) 7. [Safety & Cautions](#safety) 8. [Comparisons](#comparisons) 9. [Calculator Tools](#calculator) 10. [Citations](#citations) ## What It Is BRP (BRINP2-Related Peptide) is a 12-amino-acid peptide identified in April 2026 by Stanford researchers using an AI tool called Peptide Predictor, which scanned 20,000 human protein-coding genes and identified 2,683 potential peptides. BRP is derived from the prohormone BRINP2 (BMP/retinoic acid inducible neural specific 2) and acts specifically in the hypothalamus to regulate appetite and metabolism. Unlike GLP-1 agonists such as semaglutide, which target receptors found across the brain, gut, and pancreas, BRP's hypothalamus-specific action may explain why animal studies show appetite suppression without nausea, constipation, or muscle loss. In lean mice and minipigs, a single BRP injection reduced food intake by up to 50% within one hour. In obese mice, daily injections over two weeks caused average weight loss of 3 grams (primarily fat), with improved glucose and insulin tolerance. The treated animals showed no changes in activity levels, water intake, anxiety, or digestion. Scientists have confirmed BRP works outside known weight-loss pathways, representing a potentially novel mechanism distinct from GLP-1, GIP, and amylin receptor systems. Published in Nature (April 2026), the discovery has led to the founding of a company planning human clinical trials, though no timeline for human studies has been announced. BRP triggered a tenfold increase in neuronal activity compared to control cells in hypothalamic assays. The lead researcher has co-founded a biotech startup to advance BRP into human clinical trials, with IND-enabling studies expected to begin in late 2026. Also known as: BRINP2-Related Peptide, Natural Ozempic, Stanford Appetite Peptide ## Regulatory Status Not yet in clinical trials Discovered in April 2026 and published in Nature. A startup company has been founded to pursue human clinical trials. No FDA regulatory pathway initiated yet. Effective: April 2026 [View FDA Source](https://www.sciencedaily.com/releases/2026/04/260412221946.htm) ## Why Researchers Study It BRP represents a new paradigm in appetite regulation — a naturally occurring human peptide that targets the hypothalamus with high specificity, avoiding the systemic side effects of GLP-1 drugs. Its discovery via AI-powered proteome scanning (Peptide Predictor) also demonstrates the potential of computational methods to identify novel therapeutic peptides from the human genome. ## Proposed Mechanisms - Acts directly on hypothalamic neurons controlling appetite and metabolism - Triggers tenfold increase in neuronal activity in hypothalamic assays - Reduces food intake without affecting gut motility or peripheral organs - Preserves lean muscle mass during weight loss in animal models - Improves glucose tolerance and insulin sensitivity in obese mice ## Evidence Snapshot Low Evidence Low Medium High Study Type Model Outcome Link Animal (mouse, minipig) Lean and obese models, single and repeated injection 50% reduction in food intake (single dose); significant fat loss over 2 weeks with improved metabolic markers [Source](https://www.sciencedaily.com/releases/2026/04/260412221946.htm) ## Commonly Discussed Benefits [Appetite Regulation](/benefits/appetite-regulation)[Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) Researching BRP ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=brp) ## Safety & Cautions - Preclinical only — no human data exists yet - Long-term effects and safety profile completely unknown - Animal model results may not translate to humans - No regulatory pathway or FDA designation yet - Commercial development is at the earliest stage (startup founded) ## Comparisons See how BRP compares to related peptides: [BRP vs Orforglipron](/compare/brp-vs-orforglipron) [BRP vs Retatrutide](/compare/brp-vs-retatrutide) [BRP vs Semaglutide](/compare/brp-vs-semaglutide) [BRP vs Tirzepatide](/compare/brp-vs-tirzepatide) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Stanford scientists discover 'natural Ozempic' without side effects. ScienceDaily, April 2026 [PubMed](https://www.sciencedaily.com/releases/2026/04/260412221946.htm) 2. \[2\] Svensson KJ et al. — AI identification of BRP as a hypothalamic appetite peptide. Nature, April 2026 [PubMed](https://www.nature.com/) 3. \[3\] Scientists identify appetite-suppressing peptide that works outside known weight-loss pathways — The Debrief, April 2026 [PubMed](https://thedebrief.org/scientists-identify-appetite-suppressing-peptide-that-works-outside-known-weight-loss-pathways/) ### Keep researching in the app - Log BRP to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=brp) [Browse more peptides](/peptides) ## Related Peptides ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/orforglipron) [\+ Compare](/compare?select=orforglipron)[](https://app.peptrackerpro.com/?add=orforglipron) ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/retatrutide) [\+ Compare](/compare?select=retatrutide)[](https://app.peptrackerpro.com/?add=retatrutide) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.